Baidu
map

ISME J:中药“葛根芩连汤”可能通过改变肠道菌群治疗糖尿病

2014-10-06 MedSci MedSci原创

2014年10月3日,国际微生物生态学会会刊(The ISME Journal)在线发表一篇中国学者的研究论文,“一种中药复方改善糖尿病过程中的肠道菌群结构变化特征”。这篇论文是中国中医科学院广安门中医院仝小林团队与上海交通大学生命科学技术学院和上海系统生物医学研究中心赵立平团队合作研究的成果。The ISME Journal是国际微生物生态学界的旗舰刊物,最新影响因子为9.276。 

2014年10月3日,国际微生物生态学会会刊(The ISME Journal)在线发表一篇中国学者的研究论文,“一种中药复方改善糖尿病过程中的肠道菌群结构变化特征”。这篇论文是中国中医科学院广安门中医院仝小林团队与上海交通大学生命科学技术学院和上海系统生物医学研究中心赵立平团队合作研究的成果。The ISME Journal是国际微生物生态学界的旗舰刊物,最新影响因子为9.276。 

该论文对一种来自张仲景《伤寒论》的经方“葛根芩连汤”做了随机、双盲、安慰剂对照的糖尿病临床治疗试验,证实该中药复方具有明确而显著的降低空腹血糖和糖化血红蛋白的效果。对治疗前后粪便样品中的DNA所作的高通量测序和生物信息分析发现,药物的疗效与菌群结构变化有着密切的关系,为解释中药复方的临床效果提供了一条新的证据链。
 
该研究表明,安慰剂组和低剂量组在12周的时间里菌群结构基本在原地踏步,没有显著变化,临床症状这两个组也没有改善。随着葛根芩连汤的剂量提高,处理组志愿者的菌群结构距离开始治疗前也越远,而临床疗效也越好。研究还发现,高剂量组志愿者的菌群在用药4周后就移动到远离起点的位置,在接下来的8周里一直在这里不变,而临床症状一直持续改善。也就是说,菌群结构显著变化在先,临床症状显著改善在后,提示菌群的变化可能是症状改善的原因之一。由于使用了高通量测序和深入的统计分析,研究者从4千多种细菌中找到了与症状改善呈正相关和负相关的具体的细菌种类。用药以后,一些病菌的数量下降,而一些有益菌的数量上升。特别是一种叫做Faecalibacteriumprausnitzii的细菌在用药后显著升高,而且与空腹血糖和糖化血红蛋白呈负相关,药量越大,临床改善越好,这个菌的数量也升得越高。这种细菌已经有很多报道,是可以产生丁酸盐,具有消炎作用的有益菌。华大基因在《自然杂志》发表的糖尿病人菌群研究论文中,也发现这种细菌在病人肠道里是显著降低的。这种细菌是可以人工培养的,因此,下一步可以分离这种有益菌,对作用机制做更加深入的研究,也有望成为糖尿病人可以使用的益生菌。
 
该论文既证实了一种中药复方的临床疗效,也提供了西方医学可以接受的一种机理解释。这篇论文是中医药学界在国际刊物发表的为数不多的高影响因子论文。它也是中医学与微生物生态学学科交叉的成果,印证了我国微生物学界的泰斗之一魏曦认为“微生态学是打开中医之谜的金钥匙”的观点。

原始出处:
Xu J, Lian F, Zhao L, Zhao Y, Chen X, Zhang X, Guo Y, Zhang C, Zhou Q, Xue Z, Pang X, Zhao L, Tong X.Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula.ISME J. 2014 Oct 3. doi: 10.1038/ismej.2014.177.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (19)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=20553, encodeId=fe94205536d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:09:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19523, encodeId=e4fe19523ba, content=有争议是好事,有这么好成果代表水平!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Apr 05 12:11:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13198, encodeId=287613198a5, content=希望以后有更多的研究发表,为中医药研究提供新的思路。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11c9108528, createdName=sky263, createdTime=Wed Dec 17 23:27:00 CST 2014, time=2014-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12891, encodeId=4c8f1289181, content=需要跟多的研究吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlicehVzPC3BIG5MMT4o0D9CNdMrAdiaz1LvNJDqSoPjibHaiavyvkImlpzzneRgAwFEeCicwRjXhcHbw/132, createdBy=3f1689006, createdName=SSRIs, createdTime=Mon Dec 01 21:47:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12526, encodeId=04ea125266c, content=自己做不出来就随便怀疑,有意思嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=221.232.158.165, createdTime=Sun Nov 16 13:22:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392146, encodeId=ea45139214612, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Wed Oct 08 12:53:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12034, encodeId=88501203486, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12033, encodeId=41431203304, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12025, encodeId=eccc1202534, content=终于看了全文,还好随机之前是224人,分为四组,各56人,分析的不是ITT,而是PP人群,勉强能接受吧。另外,入选标准为新诊断的T2DM,其中HbA1c ≥ 7.0 %, FBG < 13.9 mmol/L。但基线表中HbA1c变异度(标准差)真的好小好漂亮,还有性别似乎差别很大,也不知道如何统计?真希望作者能公布原始资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:28:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12024, encodeId=3b9612024a6, content=randomly allocated to receive high (HD, n=44), moderate (MD, n=52), low dose GQD (LD, n=50) or the placebo (n=41) for 12 weeks in a double-blinded trial.---------随机做成这个样子,简直是极品! <br> 另外,我阅读了全文,没有注册,没有样本量计算,终点也是乱设的,也能发表,真是欺负搞基础研究的,不懂临床,垃圾也能发表, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:12:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
    2015-04-11 x35042875

    控制好糖尿病可能提高肝硬化患者的预后。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=20553, encodeId=fe94205536d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:09:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19523, encodeId=e4fe19523ba, content=有争议是好事,有这么好成果代表水平!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Apr 05 12:11:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13198, encodeId=287613198a5, content=希望以后有更多的研究发表,为中医药研究提供新的思路。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11c9108528, createdName=sky263, createdTime=Wed Dec 17 23:27:00 CST 2014, time=2014-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12891, encodeId=4c8f1289181, content=需要跟多的研究吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlicehVzPC3BIG5MMT4o0D9CNdMrAdiaz1LvNJDqSoPjibHaiavyvkImlpzzneRgAwFEeCicwRjXhcHbw/132, createdBy=3f1689006, createdName=SSRIs, createdTime=Mon Dec 01 21:47:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12526, encodeId=04ea125266c, content=自己做不出来就随便怀疑,有意思嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=221.232.158.165, createdTime=Sun Nov 16 13:22:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392146, encodeId=ea45139214612, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Wed Oct 08 12:53:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12034, encodeId=88501203486, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12033, encodeId=41431203304, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12025, encodeId=eccc1202534, content=终于看了全文,还好随机之前是224人,分为四组,各56人,分析的不是ITT,而是PP人群,勉强能接受吧。另外,入选标准为新诊断的T2DM,其中HbA1c ≥ 7.0 %, FBG < 13.9 mmol/L。但基线表中HbA1c变异度(标准差)真的好小好漂亮,还有性别似乎差别很大,也不知道如何统计?真希望作者能公布原始资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:28:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12024, encodeId=3b9612024a6, content=randomly allocated to receive high (HD, n=44), moderate (MD, n=52), low dose GQD (LD, n=50) or the placebo (n=41) for 12 weeks in a double-blinded trial.---------随机做成这个样子,简直是极品! <br> 另外,我阅读了全文,没有注册,没有样本量计算,终点也是乱设的,也能发表,真是欺负搞基础研究的,不懂临床,垃圾也能发表, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:12:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
    2015-04-05 223.104.5.**

    有争议是好事,有这么好成果代表水平!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=20553, encodeId=fe94205536d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:09:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19523, encodeId=e4fe19523ba, content=有争议是好事,有这么好成果代表水平!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Apr 05 12:11:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13198, encodeId=287613198a5, content=希望以后有更多的研究发表,为中医药研究提供新的思路。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11c9108528, createdName=sky263, createdTime=Wed Dec 17 23:27:00 CST 2014, time=2014-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12891, encodeId=4c8f1289181, content=需要跟多的研究吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlicehVzPC3BIG5MMT4o0D9CNdMrAdiaz1LvNJDqSoPjibHaiavyvkImlpzzneRgAwFEeCicwRjXhcHbw/132, createdBy=3f1689006, createdName=SSRIs, createdTime=Mon Dec 01 21:47:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12526, encodeId=04ea125266c, content=自己做不出来就随便怀疑,有意思嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=221.232.158.165, createdTime=Sun Nov 16 13:22:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392146, encodeId=ea45139214612, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Wed Oct 08 12:53:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12034, encodeId=88501203486, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12033, encodeId=41431203304, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12025, encodeId=eccc1202534, content=终于看了全文,还好随机之前是224人,分为四组,各56人,分析的不是ITT,而是PP人群,勉强能接受吧。另外,入选标准为新诊断的T2DM,其中HbA1c ≥ 7.0 %, FBG < 13.9 mmol/L。但基线表中HbA1c变异度(标准差)真的好小好漂亮,还有性别似乎差别很大,也不知道如何统计?真希望作者能公布原始资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:28:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12024, encodeId=3b9612024a6, content=randomly allocated to receive high (HD, n=44), moderate (MD, n=52), low dose GQD (LD, n=50) or the placebo (n=41) for 12 weeks in a double-blinded trial.---------随机做成这个样子,简直是极品! <br> 另外,我阅读了全文,没有注册,没有样本量计算,终点也是乱设的,也能发表,真是欺负搞基础研究的,不懂临床,垃圾也能发表, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:12:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
    2014-12-17 sky263

    希望以后有更多的研究发表,为中医药研究提供新的思路。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=20553, encodeId=fe94205536d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:09:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19523, encodeId=e4fe19523ba, content=有争议是好事,有这么好成果代表水平!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Apr 05 12:11:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13198, encodeId=287613198a5, content=希望以后有更多的研究发表,为中医药研究提供新的思路。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11c9108528, createdName=sky263, createdTime=Wed Dec 17 23:27:00 CST 2014, time=2014-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12891, encodeId=4c8f1289181, content=需要跟多的研究吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlicehVzPC3BIG5MMT4o0D9CNdMrAdiaz1LvNJDqSoPjibHaiavyvkImlpzzneRgAwFEeCicwRjXhcHbw/132, createdBy=3f1689006, createdName=SSRIs, createdTime=Mon Dec 01 21:47:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12526, encodeId=04ea125266c, content=自己做不出来就随便怀疑,有意思嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=221.232.158.165, createdTime=Sun Nov 16 13:22:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392146, encodeId=ea45139214612, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Wed Oct 08 12:53:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12034, encodeId=88501203486, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12033, encodeId=41431203304, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12025, encodeId=eccc1202534, content=终于看了全文,还好随机之前是224人,分为四组,各56人,分析的不是ITT,而是PP人群,勉强能接受吧。另外,入选标准为新诊断的T2DM,其中HbA1c ≥ 7.0 %, FBG < 13.9 mmol/L。但基线表中HbA1c变异度(标准差)真的好小好漂亮,还有性别似乎差别很大,也不知道如何统计?真希望作者能公布原始资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:28:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12024, encodeId=3b9612024a6, content=randomly allocated to receive high (HD, n=44), moderate (MD, n=52), low dose GQD (LD, n=50) or the placebo (n=41) for 12 weeks in a double-blinded trial.---------随机做成这个样子,简直是极品! <br> 另外,我阅读了全文,没有注册,没有样本量计算,终点也是乱设的,也能发表,真是欺负搞基础研究的,不懂临床,垃圾也能发表, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:12:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
    2014-12-01 SSRIs

    需要跟多的研究吗?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=20553, encodeId=fe94205536d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:09:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19523, encodeId=e4fe19523ba, content=有争议是好事,有这么好成果代表水平!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Apr 05 12:11:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13198, encodeId=287613198a5, content=希望以后有更多的研究发表,为中医药研究提供新的思路。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11c9108528, createdName=sky263, createdTime=Wed Dec 17 23:27:00 CST 2014, time=2014-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12891, encodeId=4c8f1289181, content=需要跟多的研究吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlicehVzPC3BIG5MMT4o0D9CNdMrAdiaz1LvNJDqSoPjibHaiavyvkImlpzzneRgAwFEeCicwRjXhcHbw/132, createdBy=3f1689006, createdName=SSRIs, createdTime=Mon Dec 01 21:47:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12526, encodeId=04ea125266c, content=自己做不出来就随便怀疑,有意思嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=221.232.158.165, createdTime=Sun Nov 16 13:22:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392146, encodeId=ea45139214612, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Wed Oct 08 12:53:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12034, encodeId=88501203486, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12033, encodeId=41431203304, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12025, encodeId=eccc1202534, content=终于看了全文,还好随机之前是224人,分为四组,各56人,分析的不是ITT,而是PP人群,勉强能接受吧。另外,入选标准为新诊断的T2DM,其中HbA1c ≥ 7.0 %, FBG < 13.9 mmol/L。但基线表中HbA1c变异度(标准差)真的好小好漂亮,还有性别似乎差别很大,也不知道如何统计?真希望作者能公布原始资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:28:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12024, encodeId=3b9612024a6, content=randomly allocated to receive high (HD, n=44), moderate (MD, n=52), low dose GQD (LD, n=50) or the placebo (n=41) for 12 weeks in a double-blinded trial.---------随机做成这个样子,简直是极品! <br> 另外,我阅读了全文,没有注册,没有样本量计算,终点也是乱设的,也能发表,真是欺负搞基础研究的,不懂临床,垃圾也能发表, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:12:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
    2014-11-16 221.232.158.165

    自己做不出来就随便怀疑,有意思嘛

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=20553, encodeId=fe94205536d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:09:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19523, encodeId=e4fe19523ba, content=有争议是好事,有这么好成果代表水平!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Apr 05 12:11:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13198, encodeId=287613198a5, content=希望以后有更多的研究发表,为中医药研究提供新的思路。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11c9108528, createdName=sky263, createdTime=Wed Dec 17 23:27:00 CST 2014, time=2014-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12891, encodeId=4c8f1289181, content=需要跟多的研究吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlicehVzPC3BIG5MMT4o0D9CNdMrAdiaz1LvNJDqSoPjibHaiavyvkImlpzzneRgAwFEeCicwRjXhcHbw/132, createdBy=3f1689006, createdName=SSRIs, createdTime=Mon Dec 01 21:47:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12526, encodeId=04ea125266c, content=自己做不出来就随便怀疑,有意思嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=221.232.158.165, createdTime=Sun Nov 16 13:22:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392146, encodeId=ea45139214612, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Wed Oct 08 12:53:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12034, encodeId=88501203486, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12033, encodeId=41431203304, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12025, encodeId=eccc1202534, content=终于看了全文,还好随机之前是224人,分为四组,各56人,分析的不是ITT,而是PP人群,勉强能接受吧。另外,入选标准为新诊断的T2DM,其中HbA1c ≥ 7.0 %, FBG < 13.9 mmol/L。但基线表中HbA1c变异度(标准差)真的好小好漂亮,还有性别似乎差别很大,也不知道如何统计?真希望作者能公布原始资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:28:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12024, encodeId=3b9612024a6, content=randomly allocated to receive high (HD, n=44), moderate (MD, n=52), low dose GQD (LD, n=50) or the placebo (n=41) for 12 weeks in a double-blinded trial.---------随机做成这个样子,简直是极品! <br> 另外,我阅读了全文,没有注册,没有样本量计算,终点也是乱设的,也能发表,真是欺负搞基础研究的,不懂临床,垃圾也能发表, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:12:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=20553, encodeId=fe94205536d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:09:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19523, encodeId=e4fe19523ba, content=有争议是好事,有这么好成果代表水平!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Apr 05 12:11:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13198, encodeId=287613198a5, content=希望以后有更多的研究发表,为中医药研究提供新的思路。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11c9108528, createdName=sky263, createdTime=Wed Dec 17 23:27:00 CST 2014, time=2014-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12891, encodeId=4c8f1289181, content=需要跟多的研究吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlicehVzPC3BIG5MMT4o0D9CNdMrAdiaz1LvNJDqSoPjibHaiavyvkImlpzzneRgAwFEeCicwRjXhcHbw/132, createdBy=3f1689006, createdName=SSRIs, createdTime=Mon Dec 01 21:47:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12526, encodeId=04ea125266c, content=自己做不出来就随便怀疑,有意思嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=221.232.158.165, createdTime=Sun Nov 16 13:22:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392146, encodeId=ea45139214612, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Wed Oct 08 12:53:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12034, encodeId=88501203486, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12033, encodeId=41431203304, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12025, encodeId=eccc1202534, content=终于看了全文,还好随机之前是224人,分为四组,各56人,分析的不是ITT,而是PP人群,勉强能接受吧。另外,入选标准为新诊断的T2DM,其中HbA1c ≥ 7.0 %, FBG < 13.9 mmol/L。但基线表中HbA1c变异度(标准差)真的好小好漂亮,还有性别似乎差别很大,也不知道如何统计?真希望作者能公布原始资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:28:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12024, encodeId=3b9612024a6, content=randomly allocated to receive high (HD, n=44), moderate (MD, n=52), low dose GQD (LD, n=50) or the placebo (n=41) for 12 weeks in a double-blinded trial.---------随机做成这个样子,简直是极品! <br> 另外,我阅读了全文,没有注册,没有样本量计算,终点也是乱设的,也能发表,真是欺负搞基础研究的,不懂临床,垃圾也能发表, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:12:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
    2014-10-08 61.135.213.213

    药的比例!叙述清楚啊!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=20553, encodeId=fe94205536d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:09:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19523, encodeId=e4fe19523ba, content=有争议是好事,有这么好成果代表水平!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Apr 05 12:11:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13198, encodeId=287613198a5, content=希望以后有更多的研究发表,为中医药研究提供新的思路。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11c9108528, createdName=sky263, createdTime=Wed Dec 17 23:27:00 CST 2014, time=2014-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12891, encodeId=4c8f1289181, content=需要跟多的研究吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlicehVzPC3BIG5MMT4o0D9CNdMrAdiaz1LvNJDqSoPjibHaiavyvkImlpzzneRgAwFEeCicwRjXhcHbw/132, createdBy=3f1689006, createdName=SSRIs, createdTime=Mon Dec 01 21:47:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12526, encodeId=04ea125266c, content=自己做不出来就随便怀疑,有意思嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=221.232.158.165, createdTime=Sun Nov 16 13:22:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392146, encodeId=ea45139214612, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Wed Oct 08 12:53:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12034, encodeId=88501203486, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12033, encodeId=41431203304, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12025, encodeId=eccc1202534, content=终于看了全文,还好随机之前是224人,分为四组,各56人,分析的不是ITT,而是PP人群,勉强能接受吧。另外,入选标准为新诊断的T2DM,其中HbA1c ≥ 7.0 %, FBG < 13.9 mmol/L。但基线表中HbA1c变异度(标准差)真的好小好漂亮,还有性别似乎差别很大,也不知道如何统计?真希望作者能公布原始资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:28:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12024, encodeId=3b9612024a6, content=randomly allocated to receive high (HD, n=44), moderate (MD, n=52), low dose GQD (LD, n=50) or the placebo (n=41) for 12 weeks in a double-blinded trial.---------随机做成这个样子,简直是极品! <br> 另外,我阅读了全文,没有注册,没有样本量计算,终点也是乱设的,也能发表,真是欺负搞基础研究的,不懂临床,垃圾也能发表, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:12:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
    2014-10-08 61.135.213.213

    药的比例!叙述清楚啊!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=20553, encodeId=fe94205536d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:09:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19523, encodeId=e4fe19523ba, content=有争议是好事,有这么好成果代表水平!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Apr 05 12:11:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13198, encodeId=287613198a5, content=希望以后有更多的研究发表,为中医药研究提供新的思路。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11c9108528, createdName=sky263, createdTime=Wed Dec 17 23:27:00 CST 2014, time=2014-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12891, encodeId=4c8f1289181, content=需要跟多的研究吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlicehVzPC3BIG5MMT4o0D9CNdMrAdiaz1LvNJDqSoPjibHaiavyvkImlpzzneRgAwFEeCicwRjXhcHbw/132, createdBy=3f1689006, createdName=SSRIs, createdTime=Mon Dec 01 21:47:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12526, encodeId=04ea125266c, content=自己做不出来就随便怀疑,有意思嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=221.232.158.165, createdTime=Sun Nov 16 13:22:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392146, encodeId=ea45139214612, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Wed Oct 08 12:53:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12034, encodeId=88501203486, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12033, encodeId=41431203304, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12025, encodeId=eccc1202534, content=终于看了全文,还好随机之前是224人,分为四组,各56人,分析的不是ITT,而是PP人群,勉强能接受吧。另外,入选标准为新诊断的T2DM,其中HbA1c ≥ 7.0 %, FBG < 13.9 mmol/L。但基线表中HbA1c变异度(标准差)真的好小好漂亮,还有性别似乎差别很大,也不知道如何统计?真希望作者能公布原始资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:28:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12024, encodeId=3b9612024a6, content=randomly allocated to receive high (HD, n=44), moderate (MD, n=52), low dose GQD (LD, n=50) or the placebo (n=41) for 12 weeks in a double-blinded trial.---------随机做成这个样子,简直是极品! <br> 另外,我阅读了全文,没有注册,没有样本量计算,终点也是乱设的,也能发表,真是欺负搞基础研究的,不懂临床,垃圾也能发表, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:12:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
    2014-10-07 dingding

    终于看了全文,还好随机之前是224人,分为四组,各56人,分析的不是ITT,而是PP人群,勉强能接受吧。另外,入选标准为新诊断的T2DM,其中HbA1c ≥ 7.0 %, FBG < 13.9 mmol/L。但基线表中HbA1c变异度(标准差)真的好小好漂亮,还有性别似乎差别很大,也不知道如何统计?真希望作者能公布原始资料

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=20553, encodeId=fe94205536d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:09:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19523, encodeId=e4fe19523ba, content=有争议是好事,有这么好成果代表水平!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Apr 05 12:11:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13198, encodeId=287613198a5, content=希望以后有更多的研究发表,为中医药研究提供新的思路。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11c9108528, createdName=sky263, createdTime=Wed Dec 17 23:27:00 CST 2014, time=2014-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12891, encodeId=4c8f1289181, content=需要跟多的研究吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlicehVzPC3BIG5MMT4o0D9CNdMrAdiaz1LvNJDqSoPjibHaiavyvkImlpzzneRgAwFEeCicwRjXhcHbw/132, createdBy=3f1689006, createdName=SSRIs, createdTime=Mon Dec 01 21:47:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12526, encodeId=04ea125266c, content=自己做不出来就随便怀疑,有意思嘛, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=221.232.158.165, createdTime=Sun Nov 16 13:22:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392146, encodeId=ea45139214612, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Wed Oct 08 12:53:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12034, encodeId=88501203486, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12033, encodeId=41431203304, content=药的比例!叙述清楚啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.135.213.213, createdTime=Wed Oct 08 09:11:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12025, encodeId=eccc1202534, content=终于看了全文,还好随机之前是224人,分为四组,各56人,分析的不是ITT,而是PP人群,勉强能接受吧。另外,入选标准为新诊断的T2DM,其中HbA1c ≥ 7.0 %, FBG < 13.9 mmol/L。但基线表中HbA1c变异度(标准差)真的好小好漂亮,还有性别似乎差别很大,也不知道如何统计?真希望作者能公布原始资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:28:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12024, encodeId=3b9612024a6, content=randomly allocated to receive high (HD, n=44), moderate (MD, n=52), low dose GQD (LD, n=50) or the placebo (n=41) for 12 weeks in a double-blinded trial.---------随机做成这个样子,简直是极品! <br> 另外,我阅读了全文,没有注册,没有样本量计算,终点也是乱设的,也能发表,真是欺负搞基础研究的,不懂临床,垃圾也能发表, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingding, createdTime=Tue Oct 07 23:12:00 CST 2014, time=2014-10-07, status=1, ipAttribution=)]
    2014-10-07 dingding

    randomly allocated to receive high (HD, n=44), moderate (MD, n=52), low dose GQD (LD, n=50) or the placebo (n=41) for 12 weeks in a double-blinded trial.---------随机做成这个样子,简直是极品!
    另外,我阅读了全文,没有注册,没有样本量计算,终点也是乱设的,也能发表,真是欺负搞基础研究的,不懂临床,垃圾也能发表

    0

相关资讯

中药新药临床试验对照药选择的问题与对策

临床试验中对照药的选择、双盲双模拟的实施、中医的病证结合、证候量化标准的制定等诸如此类的问题仍待探讨,同时也是我们广大临床研究工作者困惑的一些问题,其中以对照药的选择问题尤为突出,本文就此进行讨论,并尝试提出对策。 1对照药分类 药物临床试验中,对照药的选择可分为阳性对照药和阴性对照药。阳性药物对照试验是将受试药物与已知活性有效药物进行对照的临床试验,根据试验目的又可分为优效性试验和非劣效性或

世卫组织回应“中药是否对埃博拉有效”(视频)

8月12日,世卫组织在瑞士日内瓦就埃博拉最新疫情召开记者会,以下为记者提问“中药是否对埃博拉有效”:记者:我来自央视,有一个问题,中国也非常关切这个病毒,你觉得中国的中药是否在治疗这个病毒方面有一定的效果呢?舒琦:我想坦白的说我并不知道,因为你知道中国的中药在治疗疟疾方面是有一些新的进展,那么他可能会有效果,但是就目前来说我们并不知道,即使有一些专家是建议一些新的治疗和预防的措施,但是我们有理由认

中药临床治疗性研究方案设计要点

“神农尝百草, 一日而遇七十毒” 反映了我国古代药物效能的发现源于人体试验。事实上, 中医药学中众多的药物、治疗方法的发现, 复方的产生及其疗效的证实都来源于人体试验和反复应用的直接观察和经验总结。然而, 我们也看到, 直接观察、经验总结对科学的发展固然起着一定的作用,但是还不能被认为是真正意义的科学试验, 据此进行归纳、演绎、推理产生的结论难免有一定的片面性、局限性, 有的可能甚至是错误的。

PLoS ONE:研究揭示中药痛舒胶囊治疗乳腺增生机制

记者日前从中科院昆明动物所获悉,该所陈策实课题组与云南省药物研究所合作,研究了痛舒胶囊治疗乳腺增生症的机制。相关成果发表于《科学公共图书馆—综合》。 据了解,痛舒胶囊是我国彝族的一味传统中药复方,由云南省药物研究所制药厂生产,主要用于治疗跌打损伤、风湿性关节痛、肩周炎、痛风性关节痛和乳腺小叶增生。尽管临床试验显示该药治疗乳腺增生症具有良好的效果,但尚不了解其机制。 研究发现,痛舒胶囊可

中药新药临床试验中量表运用的问题和思考

量 表作为一种测量工具,比单一指标和单个项目的测量能获得更多、更真实、更精确的信息,因此,在现代医学领域,量表的适用范围越来越广。近10多年来,中医 研究领域也逐步开始探索运用量表学方法,使用量表测评的方法来研究、规范中医的辨证,评价中药临床疗效。这为中医药临床研究规范化和科学化提供了新的思路 和方法,有利于东西方医学的相互交流和借鉴。目 前中药新药临床试验中自觉不自觉地运用着大量的量

Chem Biol:倍半萜内酯类化合物IJ-5具有抗炎作用

来自第二军医大学、上海交通大学和华东理工大学的研究人员,从中草药中获得了一种倍半萜内酯类化合物IJ-5,证实其可通过抑制泛素连接酶UbcH5来控制TNF-α的促炎活性。这一研究成果发表在9月的Chemistry & Biology杂志上。

第二军医大学的张卫东(Weidong Zhang)教授和胡振林(Zhenlin Hu)教授是这篇论文的共同通讯作者。张卫东教授主要从事天然药物化学、重要药效物质基础和创新药物研究,发表SCI论文350多篇。胡振林教授的研究方向为抗炎和免疫调控药物的基础和应用研究,发表SCI论文30余篇。

肿瘤坏死因子(TNF)是一类具有多种生物效应的细胞因子,它通过和细胞膜上的特异性的受体结合,实现促进细胞生长,分化,凋亡及诱发炎症等生物学效应。TNF-α属于TN

Baidu
map
Baidu
map
Baidu
map
Baidu
map